In vitro growth inhibition percent (GI%) for the NCI60 cancer cell lines upon treatment with 10 μM of compounds (2b–d, 3a–d and 4a–d)^a.

	2b	2c	2d	3a	3b	3c	3d	4a	4b	4c	4d
Leukaemia
CCRF-CEM	—	15.45	—	—	13.30	32.30	29.71	—	12.89	22.80	—
HL-60(TB)	20.88	49.95	43.38	44.03	49.83	57.98	51.77	31.31	15.01	17.28	—
K-652	—	31.45	—	11.78	30.20	44.30	42.83	16.46	16.20	23.12	10.67
MOLT-4	—	24.34	11.64	—	19.35	38.07	29.08	—	—	26.34	—
RPMI-8226	—	14.16	—	—	—	41.51	25.03	—	—	19.73	—
SR	—	—	—	—	—	—	—	—	—	—	—
Non-small cell lung cancer
A549/ATCC	15.77	—	10.16	16.44	—	33.50	16.81	—	31.03	36.61	24.90
EKVX	—	12.04	—	—	10.91	20.38	20.92	—	39.92	60.74	13.10
HOP-62	16.84	—	—	12.77	—	—	—	—	75.65	65.34	36.77
HOP-92	19.25	33.01	—	14.74	25.21	45.40	34.25	15.08	65.67	63.28	34.62
NCI-H226	24.21	22.53	—	18.61	28.68	46.54	37.93	—	51.64	76.22	21.35
NCI-H23	12.73	—	—	—	—	12.20	—	—	28.19	25.17	—
NCI-H322M	7.12	—	—	—	—	13.28	—	—	21.55	17.30	—
NCI-H460	13.27	—	—	—	—	13.48	—	—	26.13	22.56	—
NCI-H522	25.94	30.52	12.91	16.01	25.38	37.48	29.73	16.81	45.02	58.72	44.57
Colon cancer
COLO 205	—	—	—	—	—	22.66	—	—	—	—	—
HCC-2998	—	—	—	—	—	12.17	—	—	12.64	—	—
HCT-116	33.39	22.23	—	22.79	18.51	40.70	25.73	10.37	33.96	35.64	19.81
HCT-15	—	13.42	15.77	—	13.00	45.64	24.97	—	20.05	27.19	—
HT29	—	37.56	10.72	—	13.44	61.63	51.51	—	—	13.41	—
KM12	—	—	—	—	—	27.77	19.05	—	12.78	15.07	—
SW-620	—	10.78	—	—	—	37.21	11.21	—	14.48	19.46	—
CNS cancer
SF-268	24.67	—	—	21.56	—	18.20	12.95	—	56.58	50.66	22.32
SF-295	25.73	10.37	—	27.87	10.01	29.81	11.51	—	63.10	58.52	32.25
SF-539	45.33	—	—	24.06	—	28.21	15.58	16.91	50.95	73.77	32.27
SNB-19	18.35	—	—	16.70	—	10.67	—	—	56.32	53.96	44.48
SNB-75	23.60	—	—	—	—	—	—	—	82.51	92.38	88.04
U251	33.40	13.78	—	39.15	—	31.17	15.75	—	52.85	44.68	13.13
Melanoma
LOX IMVI	10.55	14.24	—	—	—	14.22	—	—	23.57	15.29	11.10
MALME-3M	—	—	—	—	—	—	—	—	41.38	57.24	26.17
M14	—	—	—	—	—	12.41	—	—	—	12.25	—
MDA-MB-435	—	—	—	—	—	—	—	—	—	16.03	—
SK-MEL-2	—	—	—	—	—	—	—	—	21.29	12.63	—
SK-MEL-28	—	—	—	—	—	—	—	—	14.16	17.90	—
SK-MEL-5	—	11.85	—	—	13.82	22.36	15.98	—	25.68	38.14	10.99
UACC-257	—	—	—	—	—	24.66	—	—	22.89	45.85	17.42
UACC-62	11.33	11.42	—	—	13.95	22.80	17.58	13.24	30.66	37.29	22.83
Ovarian cancer
IGROV1	—	—	—	—	—	—	—	—	—	19.45	—
OVCAR-3	—	—	—	—	—	13.71	—	—	24.80	30.28	—
OVCAR-4	73.14	—	—	49.74	—	18.42	14.97	—	39.53	42.76	20.15
OVCAR-5	—	—	—	—	—	—	—	—	16.89	—	—
OVCAR-8	48.04	—	—	27.14	10.81	16.16	—	21.20	45.16	46.89	23.86
NCI/ADR-RES	37.17	12.03	—	20.64	13.45	27.59	14.93	10.32	36.47	58.37	—
SK-OV-3	26.25	—	—	—	—	11.73	—	—	60.37	55.46	11.69
Renal cancer
786–0	84.82	—	—	38.26	—	21.29	12.30	—	75.34	69.78	55.92
A498	—	—	—	—	—	—	—	—	28.08	35.57	—
ACHN	26.83	—	—	45.51	—	14.60	—	—	53.35	48.98	37.30
CAKI-1	24.10	10.99	—	21.66	—	32.89	16.99	—	69.32	64.15	44.00
RXF 393	28.91	—	—	19.19	10.29	29.76	12.49	—	58.43	90.21	48.96
SN12C	17.08	14.07	—	—	19.06	29.81	27.59	—	27.12	25.44	—
TK-10	17.90	—	—	—	—	—	—	—	22.42	15.83	—
UO-31	26.71	11.53	—	14.25	12.89	32.10	17.01	—	13.97	49.11	10.06
Prostate cancer
PC-3	—	18.97	—	—	—	57.37	35.47	—	28.37	40.85	—
DU-145	—	—	—	—	—	24.93	18.41	—	22.16	26.65	—
Breast cancer
MCF7	—	—	10.82	—	17.40	27.06	12.55	—	36.26	41.49	11.76
MDA-MB-231/ATCC	39.26	—	—	21.72	—	—	—	10.65	49.52	52.93	31.92
HS 578T	24.34	—	—	16.76	—	13.31	—	19.87	74.34	84.42	48.85
BT-549	—	—	15.75	11.73	—	43.62	18.08	19.15	35.72	41.46	11.94
T-47D	25.99	23.03	13.50	10.38	33.18	68.67	46.84	15.89	26.75	44.55	12.46
MDA-MB-468	14.26	—	—	—	—	19.68	—	—	37.89	49.44	—
Mean	16.01	—	—	—	—	23.91	12.62	—	34.42	39.54	14.01

^aGI% < 10.